Evidence map›Paper›PMID 34591291›Full record

ReviewInternational journal of hematology2022

Successful rituximab treatment of an elderly Japanese patient with HHV8-positive, HIV-negative multicentric Castleman disease.

Hajime Kaga, Honami Kurahashi, Arisa Kubota, Yoshiaki Hatano, Hiroshi Nanjo, Hideki Wakui, Naoto Takahashi

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in International journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hajime KagaDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita City, Akita, 010-8543, Japan. kaga1@med.akita-u.ac.jp.
Honami KurahashiDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita City, Akita, 010-8543, Japan.
Arisa KubotaDepartment of Hematology, Nephrology and Rheumatology, Noshiro Kosei Medical Center, Noshiro, Japan.
Yoshiaki HatanoDepartment of Hematology, Nephrology and Rheumatology, Noshiro Kosei Medical Center, Noshiro, Japan.
Hiroshi NanjoDivision of Clinical Pathology, Akita University Hospital, Akita, Japan.
Hideki WakuiDepartment of Life Science, Akita University Graduate School of Engineering Science, Akita, Japan.
Naoto TakahashiDepartment of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita City, Akita, 010-8543, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human herpesvirus-8 (HHV8)-positive, human immunodeficiency virus (HIV)-negative multicentric Castleman disease (MCD) is a rare and age-related lymphoproliferative disorder caused by cytokine storm. Rituximab treatment is currently recommended because B-cell depletion eliminates the primary reservoir for HHV8. We report the first case of effective rituximab treatment of a Japanese patient (an 87-year-old woman) with this disorder. Her inflammatory symptoms and lymphadenopathy improved after medium-dose steroid therapy, but these symptoms recurred during steroid tapering. After one course of rituximab therapy, she achieved sustained remission. HHV8-associated MCD should be considered as a possible diagnosis in HIV-negative patients with inflammatory symptoms and lymphadenopathy.

Indexed as

Administration, OralAdultAgedAged, 80 and overAge FactorsAsian PeopleB-Lymphocyte SubsetsCastleman DiseaseFemaleHIVHumansMaleMiddle AgedPrednisoloneRecurrenceRemission InductionPrednisoloneRituximabHuman herpesvirus-8Human immunodeficiency virusMulticentric Castleman diseaseRituximab

Identifiers

PMID34591291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.